Preoperative parenteral parecoxib, and follow-up oral valdecoxib reduce length of stay and improve quality of patient recovery after laparoscopic cholecystectomy surgery

Tong J. Gan, Girish P. Joshi, Eugene Viscusi, Raymond Y. Cheung, William Dodge, John G. Fort, Connie Chen

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

In this randomized, double-blinded, placebo-controlled study, we evaluated the effects of preoperative IV parecoxib sodium (parecoxib) followed by postoperative oral valdecoxib on length of stay, resource utilization, opioid-related side effects, and patient recovery after elective laparoscopic cholecystectomy. Patients were randomized to receive a single IV dose of parecoxib 40 mg (n = 134) or placebo (n = 129) 30-45 min before the induction of anesthesia. Six to 12 h after the IV dose, the parecoxib group received a single oral dose of valdecoxib 40 mg, followed by valdecoxib 40 mg once daily on postoperative Days 1-4 and then 40 mg once daily as needed on Days 5-7. Patients in the parecoxib/valdecoxib group had a shorter length of stay in the postanesthesia care unit (78 ± 47 min) compared with those taking placebo (90 ± 49 min; P < 0.05). Patients in the parecoxib/valdecoxib group also had reduced pain intensity and, after discharge, experienced a significant reduction in vomiting in the first 24 h, slept better, returned to normal activity earlier, and expressed greater satisfaction than placebo patients (P < 0.05). Preoperative parecoxib followed by postoperative valdecoxib is a valuable adjunct for treating pain and improving patient outcome after laparoscopic cholecystectomy.

Original languageEnglish (US)
Pages (from-to)1665-1673
Number of pages9
JournalAnesthesia and Analgesia
Volume98
Issue number6
StatePublished - Jun 2004

Fingerprint

Laparoscopic Cholecystectomy
Laparoscopy
Length of Stay
Placebos
Pain
parecoxib
valdecoxib
Patient Satisfaction
Opioid Analgesics
Vomiting
Anesthesia

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Preoperative parenteral parecoxib, and follow-up oral valdecoxib reduce length of stay and improve quality of patient recovery after laparoscopic cholecystectomy surgery. / Gan, Tong J.; Joshi, Girish P.; Viscusi, Eugene; Cheung, Raymond Y.; Dodge, William; Fort, John G.; Chen, Connie.

In: Anesthesia and Analgesia, Vol. 98, No. 6, 06.2004, p. 1665-1673.

Research output: Contribution to journalArticle

Gan, Tong J. ; Joshi, Girish P. ; Viscusi, Eugene ; Cheung, Raymond Y. ; Dodge, William ; Fort, John G. ; Chen, Connie. / Preoperative parenteral parecoxib, and follow-up oral valdecoxib reduce length of stay and improve quality of patient recovery after laparoscopic cholecystectomy surgery. In: Anesthesia and Analgesia. 2004 ; Vol. 98, No. 6. pp. 1665-1673.
@article{48747b8ac1524c88b475de6617e8b9b9,
title = "Preoperative parenteral parecoxib, and follow-up oral valdecoxib reduce length of stay and improve quality of patient recovery after laparoscopic cholecystectomy surgery",
abstract = "In this randomized, double-blinded, placebo-controlled study, we evaluated the effects of preoperative IV parecoxib sodium (parecoxib) followed by postoperative oral valdecoxib on length of stay, resource utilization, opioid-related side effects, and patient recovery after elective laparoscopic cholecystectomy. Patients were randomized to receive a single IV dose of parecoxib 40 mg (n = 134) or placebo (n = 129) 30-45 min before the induction of anesthesia. Six to 12 h after the IV dose, the parecoxib group received a single oral dose of valdecoxib 40 mg, followed by valdecoxib 40 mg once daily on postoperative Days 1-4 and then 40 mg once daily as needed on Days 5-7. Patients in the parecoxib/valdecoxib group had a shorter length of stay in the postanesthesia care unit (78 ± 47 min) compared with those taking placebo (90 ± 49 min; P < 0.05). Patients in the parecoxib/valdecoxib group also had reduced pain intensity and, after discharge, experienced a significant reduction in vomiting in the first 24 h, slept better, returned to normal activity earlier, and expressed greater satisfaction than placebo patients (P < 0.05). Preoperative parecoxib followed by postoperative valdecoxib is a valuable adjunct for treating pain and improving patient outcome after laparoscopic cholecystectomy.",
author = "Gan, {Tong J.} and Joshi, {Girish P.} and Eugene Viscusi and Cheung, {Raymond Y.} and William Dodge and Fort, {John G.} and Connie Chen",
year = "2004",
month = "6",
language = "English (US)",
volume = "98",
pages = "1665--1673",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Preoperative parenteral parecoxib, and follow-up oral valdecoxib reduce length of stay and improve quality of patient recovery after laparoscopic cholecystectomy surgery

AU - Gan, Tong J.

AU - Joshi, Girish P.

AU - Viscusi, Eugene

AU - Cheung, Raymond Y.

AU - Dodge, William

AU - Fort, John G.

AU - Chen, Connie

PY - 2004/6

Y1 - 2004/6

N2 - In this randomized, double-blinded, placebo-controlled study, we evaluated the effects of preoperative IV parecoxib sodium (parecoxib) followed by postoperative oral valdecoxib on length of stay, resource utilization, opioid-related side effects, and patient recovery after elective laparoscopic cholecystectomy. Patients were randomized to receive a single IV dose of parecoxib 40 mg (n = 134) or placebo (n = 129) 30-45 min before the induction of anesthesia. Six to 12 h after the IV dose, the parecoxib group received a single oral dose of valdecoxib 40 mg, followed by valdecoxib 40 mg once daily on postoperative Days 1-4 and then 40 mg once daily as needed on Days 5-7. Patients in the parecoxib/valdecoxib group had a shorter length of stay in the postanesthesia care unit (78 ± 47 min) compared with those taking placebo (90 ± 49 min; P < 0.05). Patients in the parecoxib/valdecoxib group also had reduced pain intensity and, after discharge, experienced a significant reduction in vomiting in the first 24 h, slept better, returned to normal activity earlier, and expressed greater satisfaction than placebo patients (P < 0.05). Preoperative parecoxib followed by postoperative valdecoxib is a valuable adjunct for treating pain and improving patient outcome after laparoscopic cholecystectomy.

AB - In this randomized, double-blinded, placebo-controlled study, we evaluated the effects of preoperative IV parecoxib sodium (parecoxib) followed by postoperative oral valdecoxib on length of stay, resource utilization, opioid-related side effects, and patient recovery after elective laparoscopic cholecystectomy. Patients were randomized to receive a single IV dose of parecoxib 40 mg (n = 134) or placebo (n = 129) 30-45 min before the induction of anesthesia. Six to 12 h after the IV dose, the parecoxib group received a single oral dose of valdecoxib 40 mg, followed by valdecoxib 40 mg once daily on postoperative Days 1-4 and then 40 mg once daily as needed on Days 5-7. Patients in the parecoxib/valdecoxib group had a shorter length of stay in the postanesthesia care unit (78 ± 47 min) compared with those taking placebo (90 ± 49 min; P < 0.05). Patients in the parecoxib/valdecoxib group also had reduced pain intensity and, after discharge, experienced a significant reduction in vomiting in the first 24 h, slept better, returned to normal activity earlier, and expressed greater satisfaction than placebo patients (P < 0.05). Preoperative parecoxib followed by postoperative valdecoxib is a valuable adjunct for treating pain and improving patient outcome after laparoscopic cholecystectomy.

UR - http://www.scopus.com/inward/record.url?scp=2442691835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442691835&partnerID=8YFLogxK

M3 - Article

C2 - 15155324

AN - SCOPUS:2442691835

VL - 98

SP - 1665

EP - 1673

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 6

ER -